BI 1181181 / Boehringer Ingelheim, AbbVie - LARVOL DELTA

Synthesis of Beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors BI 1147560 and BI 1181181 Labeled with Carbon-14 and Deuterium. (PubMed, J Labelled Comp Radiopharm) - "The use of advanced key chiral intermediates like 3 and 5 shortened the carbon 14 syntheses of these two compounds to five and six steps respectively and helped in preparing them with very high chemical purity and enantiomeric excess without deviating from the process chemistry route. For the deuterium synthesis, oxetan-3-ylmethanamine [ H ]-7 and 2-fluoro-2-methylpropan-1-amine [ H ]-9 were prepared then used with the chiral intermediate 5 to furnish deuterium labeled 1 and 2 respectively."

Journal • Alzheimer's Disease • CNS Disorders • APP

Vitae Pharmaceuticals reports fourth quarter and full year 2014 operating and financial results (GlobeNewswire) - "...in a Phase 1 clinical trial of BI 1181181, skin reactions were observed in some patients, prompting BI to place the compound on a voluntary clinical hold while the finding was investigated. BI has completed its analysis and concluded that skin reactions are an obstacle for further development. Therefore, BI has decided to move forward with the development of a structurally different compound, BI 1147560, which was also discovered and advanced through preclinical development as part of the BACE collaboration. BI currently expects to start the initial Phase 1 clinical trial of BI 1147560 by the end of 2015."

Discontinued • Alzheimer's Disease

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Boehringer Ingelheim; N=32 -> 0 ; Not yet recruiting -> Withdrawn

Enrollment change • Trial withdrawal • Biosimilar